{"success":true,"data":{"pressRelease":{"id":"170639","rtpr_id":"nPRrF4130a-20261015","ticker":"4BB","exchange":"LSE","all_tickers":["4BB"],"title":"REG-4basebio Plc: Results of Capital Raise","author":"PR Newswire","published_at":"2026-10-15T14:15:48.413Z","article_body":"THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR\nINDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,\nSOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR\nDISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES IN THIS\nANNOUNCEMENT.\n\nThe information contained within this announcement is deemed by the Group to\nconstitute inside information as stipulated under the Market Abuse Regulation\n(EU) No. 596/2014 (as it forms part of domestic law by virtue of the European\nUnion (Withdrawal) Act 2018). Upon the publication of this announcement via\nthe Regulatory Information Service, this inside information is now considered\nto be in the public domain.\n\n15 October 2026\n\n4basebio PLC\n\n(“4basebio” or the “Company”)\n\nResults of Capital Raise\n\nCAMBRIDGE, UK – 15 October 2026 - 4basebio PLC (AIM: 4BB), a specialist in\nsynthetic DNA manufacturing for next-generation genomic medicines and advanced\ntherapies, is pleased to announce that it has conditionally raised gross\nproceeds of approximately £15.0 million through (i) the placing of 2,664,080\nnew Ordinary Shares  (the “Placing Shares”, comprising 485,436 VCT\nplacing shares and 2,178,644 ordinary placing shares) to institutional\ninvestors including certain existing shareholders (the “Placing”), and\n(ii) subscriptions for 1,025,239 new Ordinary Shares (the “Subscription\nShares”) by certain directors and existing shareholders including those\npertaining to the Subscription & Set-Off Agreement as defined below (the\n“Subscription”, and, together with the Retail Offer (as defined below) the\n“Capital Raise”). The Capital Raise is subject to shareholder approval.\n\nM&G Investment Management Limited (“M&G”), which currently holds 12.62 per\ncent. of the existing ordinary share capital of the Company, has subscribed\nfor 465,830 Placing Shares. Elevage Medical Technologies LLC, which currently\nholds 17.16 per cent. of the existing ordinary share capital of the Company,\nhas subscribed for 256,504 Placing Shares. The Participation of the Deutsche\nBalaton group, which currently holds 32.95 per cent. of the existing ordinary\nshare capital of the Company, in the Capital Raise is described in further\ndetail below under “2Invest Subscription and Set Off”.\n\nDirectors and Officers’ Subscriptions\n\nCertain directors and officers of the Company – namely Amy Walker, Richard\nBungay, Heikki Lanckriet and Hansjörg Plaggemars – have subscribed for\n54,366 Subscription Shares, representing aggregate gross proceeds of £0.3\nmillion pursuant to the Subscription.\n\n Name                  Position                 Number of Subscription Shares  Aggregate Subscription Amount  Resultant Shareholding  % of Enlarged Share Capital following completion of the Capital Raise[1] (#_ftn1)  \n Amy Walker            Chief Executive Officer  9,708                          £49,996.20                     58,237                  0.30%                                                                              \n Richard Bungay        Chief Financial Officer  3,883                          £19,997.45                     3,883                   0.02%                                                                              \n Heikki Lanckriet      Non-executive Director   38,834                         £199,995.10                    1,151,522               5.96%                                                                              \n Hansjörg Plaggemars   Non-executive Director   1,941                          £9,996.15                      9,608                   0.05%                                                                              \n\n2Invest Subscription and Set-off\n\nThe Company currently has a fully drawn €25 million loan facility with\n2Invest AG, a member of the Deutsche Balaton group (the “Shareholder\nLoan”). Entities in the Deutsche Balaton group currently hold, in aggregate,\n32.95 per cent. of the existing ordinary share capital of the Company.\nConcurrently with the Placing, 2Invest AG has agreed under the terms of a\nsubscription and set-off agreement dated 15 October 2026 (the “Subscription\n& Set-Off Agreement”) (i) to subscribe for 194,174 Subscription Shares in\ncash at the Issue Price, for an aggregate amount of approximately £1 million\nand (ii) to subscribe for an additional 776,699  Subscription Shares at the\nIssue Price, for an aggregate amount of approximately £4 million, payment of\nwhich shall be satisfied through the set-off against repayment of an\nequivalent amount of principal and accrued interest outstanding under the\nShareholder Loan, reducing the outstanding balance under the Shareholder Loan\nto the principal sum of €21,083,234[2] (#_ftn2) (the “2Invest Subscription\n& Set-Off”). The maturity date of the Shareholder Loan will also be extended\nby two years to 31 October 2030.\n\nThe 2Invest Subscription & Set-Off and the amendment of the Shareholder Loan\nare conditional upon completion of the Placing and the remainder of the\nSubscriptions.\n\nRelated Party Transaction\n\nThe amendment to the Shareholder Loan, pursuant to the Subscription & Set-Off\nAgreement to allow for the Subscription, is a related party transaction\npursuant to Rule 13 of the AIM Rules for Companies (the “Related Party\nTransaction”).\n\nHansjörg Plaggemars is a director of the Company and Managing Director of\n2Invest AG. As such, the Directors, with the exception of Hansjörg\nPlaggemars, having consulted with the Company's Nominated Adviser, Cairn\nFinancial Advisers LLP, consider the terms of the Related Party Transaction to\nbe fair and reasonable insofar as the Company’s AIM shareholders are\nconcerned.\n\nRetail Offer\n\nAlongside the Placing and the Subscription, the Company is proposing to raise\nup to an additional £0.5 million (before expenses) by way of a retail offer\nvia the Bookbuild Platform (the “Retail Offer”). A separate announcement\nwill be made shortly regarding the Retail Offer and its terms and conditions.\nFor the avoidance of doubt the Retail Offer forms no part of the Placing. No\npart of the Placing is conditional on the Retail Offer proceeding or on any\nminimum take-up under the Retail Offer.\n\nGeneral Meeting\n\nThe Capital Raise is conditional on shareholder approval. Accordingly, the\nCompany will convene a general meeting (the “General Meeting”) at which\nshareholders will be asked to consider and, if thought fit, pass the required\nshareholder resolutions approving the grant of new authorities to the\nDirectors to allot the Placing Shares, Subscription Shares and Retail Shares\n(the “New Shares”) and to disapply statutory pre-emption rights in respect\nof such allotments (the “Resolutions”).\n\nIt is expected that the shareholder circular and notice of General Meeting\n(the “Shareholder Circular”) will be posted within three Business Days and\nthe General Meeting will be held on or around 6 November 2026. Further details\nwill be announced in due course.\n\nAdmission and Total Voting Rights\n\nFollowing the General Meeting, the Company will make applications for the\nadmission of 2,664,080 Placing Shares, 1,025,239 Subscription Shares and the\nRetail Shares to trading on AIM (“Admission”).\n\nIt is expected that Admission of the VCT Placing Shares will occur at 8.00\na.m. on or around 9 November 2026 (“First Admission”). Admission of the\nremainder of the New Shares is expected to occur at 8.00 a.m. on or around 10\nNovember 2026, one business day following First Admission (“Second\nAdmission”).\n\nAdmission is conditional, inter alia, upon Admission becoming effective, the\nPlacing Agreement not having been terminated and becoming unconditional, and\nupon the approval of the Resolutions by Shareholders at the General Meeting.\n\nExpected Timetable of Principal Events\n\n Announcement of the Capital Raise                                                                                                                    15 October 2026                               \n Announcement of the results of the Placing                                                                                                           15 October 2026                               \n Launch of Retail Offer                                                                                                                               15 October 2026                               \n Close of Retail Offer                                                                                                                                21 October 2026                               \n General Meeting                                                                                                                                      10.00 a.m. on 6 November 2026                 \n Admission and commencement of dealings in the VCT Placing Shares on AIM (First Admission)                                                            8:00 a.m. on 9                                \n                                                                                                                                                      \t\t\tNovember 2026                              \n Crediting of the VCT Placing Shares to stock accounts in CREST                                                                                       As soon as practicable after 8:00 a.m. on 9   \n                                                                                                                                                      \t\t\tNovember 2026                              \n Admission and commencement of dealings in the Non-VCT Placing Shares, Subscription Shares and Retail Offer Shares on AIM (Second Admission)          8:00 a.m. on                                  \n                                                                                                                                                      \t\t\t10 November 2026                           \n Crediting of the Non-VCT Placing Shares, Subscription Shares and Retail Offer Shares to stock accounts in CREST                                      As soon as practicable after 8:00 a.m. on 10  \n                                                                                                                                                      \t\t\tNovember 2026                              \n Expected date of despatch of definitive share certificates for the Placing Shares, Subscription Shares and Retail Offer Shares in certificated form  By no later than 16 November 2026             \n\nEach of the times and dates above refer to London time and are subject to\nchange. Any such change will be notified to shareholders by an announcement\nthrough a Regulatory Information Service.\n\nThe person responsible for the release of this announcement on behalf of the\nCompany is Richard Bungay.\n\nContact Details\n\n4basebio PLC\n\n+44 (0)12 2396 7943\n\nDr. Amy Walker – Chief Executive Officer\n\nRichard Bungay – Chief Financial Officer\n\nRBC Capital Markets (Global Co-ordinator, Joint Bookrunner and Joint Corporate\nBroker)\n\nT: +44 (0)20 7653 4000\n\nKathryn Deegan – ECM\n\nMax Avison – ECM Syndicate\n\nSandrine Cailleteau – Healthcare Advisory\n\nCavendish Capital Markets Limited (Joint Bookrunner and Joint Corporate\nBroker)\n\nT: +44 (0)20 7220 0500\n\nGeoff Nash, Andrea Callaghan – Corporate Finance\n\nNigel Birks – Healthcare Specialist Sales\n\nCairn Financial Advisers LLP (Nominated Adviser)\n\nT: +44 (0)20 7213 0880\n\nJo Turner, Sandy Jamieson, Ed Downes\n\nICR Healthcare (Media and Investor Relations)\n\nT: +44 (0)20 3707 5700\n\nJessica Hodgson / Ashley Tapp / Philip Marriage\n\nAbout 4basebio\n\n4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the\nuse of synthetic DNA to enable next-generation therapeutics and vaccines.\nThrough its proprietary enzymatic DNA synthesis platform, 4basebio produces\nGMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability,\novercoming the limitations of plasmid-based systems. The company offers\napplication-specific DNA constructs tailored to the diverse needs of gene\ntherapies, genome editing, mRNA production, and DNA vaccines, helping partners\naccelerate proof-of-concept studies and reach clinical milestones more\nefficiently while maintaining the highest standards of safety and quality.\n\nFor more information, visit 4basebio.com  (https://www.4basebio.com/).\n\nForward-looking statements\n\nThis announcement may contain certain statements about the future outlook for\n4basebio. Although the directors believe their expectations are based on\nreasonable assumptions, any statements about future outlook may be influenced\nby factors that could cause actual outcomes and results to be materially\ndifferent.\n\n 1     Details of the person discharging managerial responsibilities / person closely associated                                                                                                             \n a)    Name                                                                                               1. Amy Walker                                                                                      \n                                                                                                          2. Richard Bungay                                                                                  \n                                                                                                          3. Heikki Lanckriet                                                                                \n                                                                                                          4. Hansjörg Plaggemars                                                                             \n 2     Reason for the notification                                                                                                                                                                           \n a)    Position/status                                                                                    1. Chief Executive Officer                                                                         \n                                                                                                          2. Chief Financial Officer                                                                         \n                                                                                                          3. Non-Executive Director                                                                          \n                                                                                                          4. Non-Executive Director                                                                          \n b)    Initial notification /Amendment                                                                    Initial notification                                                                               \n 3     Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor                                                                                         \n a)    Name                                                                                               4basebio plc                                                                                       \n b)    LEI                                                                                                213800E2DX9EAIUNCB30                                                                               \n 4     Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted     \n a)    Description of the financial instrument, type of instrument Identification code                    Ordinary Shares of 1 euro each in the Company  GB00BMCLYF79                                        \n b)    Nature of the transaction                                                                          Subscription for Ordinary Shares                                                                   \n c)    Price(s) and volume(s)                                                                             Purchase of shares:                                                                                \n       Price                                                                                              Volume(s)                                                                                          \n i     £50,000                                                                                            9,708                                                                                              \n ii.   £20,000                                                                                            3,883                                                                                              \n iii.  £200,000                                                                                           38,834                                                                                             \n iv.   £10,000                                                                                            1,941                                                                                              \n d)    Aggregated information - Aggregated volume - Price - Total Value                                   54,366515 GBp £280,000                                                                             \n e)    Date of the transaction                                                                            Subscription 15 October 2026, to settle 10 November 2026 subject to shareholder approval           \n f)    Place of the transaction                                                                           LSE, AIM Market                                                                                    \n\nIMPORTANT NOTICES\n\nNeither this Announcement, nor any copy of it, may be taken or transmitted,\npublished or distributed, directly or indirectly, in or into the United\nStates, Canada, Australia, South Africa or Japan or to any persons in any of\nthose jurisdictions or any other jurisdiction where to do so would constitute\na violation of the relevant securities laws of such jurisdiction or to any\npersons in any of those jurisdictions. This Announcement is for information\npurposes only and does not constitute an offer to sell or issue, or the\nsolicitation of an offer to buy, acquire or subscribe for any shares in the\ncapital of the Company in the United States, Canada, Australia, South Africa\nor Japan or any other state or jurisdiction in which such offer or\nsolicitation is not authorised or to any person to whom it is unlawful to make\nsuch offer or solicitation. Any failure to comply with these restrictions may\nconstitute a violation of securities laws of such jurisdictions.\n\nThe Placing Shares referred to herein have not been, and will not be,\nregistered under the United States Securities Act of 1933, (the “U.S.\nSecurities Act”), or with any securities regulatory authority of any state\nor other jurisdiction of the United States and may not be offered or sold,\npledged, taken up, exercised, resold, renounced, transferred or delivered,\ndirectly or indirectly in, into or within the United States absent\nregistration under the U.S. Securities Act, except pursuant to an exemption\nfrom, or in a transaction not subject to, the registration requirements of the\nU.S. Securities Act and in compliance with any applicable securities laws of\nany state or other jurisdiction of the United States. No public offering of\nthe shares referred to in this Announcement is being made in the United\nStates.\n\nThe Placing Shares are being offered and sold by the Company (i) to persons\noutside the United States in offshore transactions as defined in, and pursuant\nto, Regulation S under the Securities Act and (ii) to a limited number of\n“qualified institutional buyers” (as such term is used in Rule 144A under\nthe Securities Act) in the United States in non-public transactions in\nreliance on Section 4(a)(2) of the Securities Act.\n\nAll offers of Placing Shares will be made pursuant to an exemption from the\nrequirement to produce a prospectus under the Prospectus Regulation\n(Regulation (EU) 2017/1129) (the “Prospectus Regulation”) in relevant\nmember states of the European Economic Area (“EEA”) and under the UK\nPublic Offers and Admissions to Trading Regulations 2024 (“POATRs”). This\nAnnouncement is not being distributed by, nor has it been approved for the\npurposes of section 21 of the Financial Services and Markets Act 2000 (\"FSMA\")\nby, a person authorised under FSMA. This Announcement is being distributed to\npersons in the United Kingdom only in circumstances in which section 21(1) of\nFSMA does not apply. Members of the public are not eligible to take part in\nthe Placing.\n\nThis announcement is being distributed only to, and is directed only at: (a)\nif in the United Kingdom, persons who are “qualified investors” within the\nmeaning of Paragraph 15 of Schedule 1 of the POATRs who (i) are persons who\nhave professional experience in matters relating to investments falling within\nArticle 19(5) of the Financial Services and Markets Act (Financial Promotion)\nOrder 2005, as amended (the \"Order\"); or (ii) are persons who are high net\nworth entities falling within Article 49(2)(a) to (d) of the Order (and only\nwhere the conditions contained in those Articles have been, or will at the\nrelevant time be, satisfied); (b) if in the EEA, persons in member states who\nare \"qualified investors\" within the meaning of Article 2(e) of the Prospectus\nRegulation (\"Qualified Investors\"); and (c) persons to whom it may otherwise\nbe lawfully communicated, (all such persons together being referred to as\n\"Relevant Persons\"). This announcement must not be acted on or relied on by\npersons who are not Relevant Persons in the United Kingdom and in any member\nstate of the EEA. Any investment or investment activity to which this\nannouncement relates is available only to Relevant Persons in the United\nKingdom and in any member state of the EEA, and will be engaged in only with\nsuch persons.\n\nCavendish is authorised and regulated by the FCA in the United Kingdom and is\nacting as joint bookrunner, joint broker and retail offer coordinator\nexclusively for the Company and no one else in connection with this\nAnnouncement or any future transaction in connection with it. Cavendish will\nnot regard any other person as a client and will not be responsible to anyone\nother than the Company for providing the protections afforded to their clients\nnor for the giving of advice in relation to any transaction, matter or\narrangement of securities of the Company referred to in this Announcement.\nNeither Cavendish nor any of its affiliates, directors or employees owes or\naccepts any duty, liability or responsibility whatsoever (whether direct or\nindirect, consequential, whether in contract, tort, in delict, under statute\nor otherwise) to any person who is not a client of Cavendish in connection\nwith the Placing or any matter referred to in this Announcement.\n\nRBC is authorised by the Prudential Regulation Authority (“PRA”) and\nregulated by the FCA and the PRA in the United Kingdom, and is acting as joint\nbroker, global co-ordinator and joint bookrunner exclusively for the Company\nand no one else in connection with this Announcement or any future transaction\nin connection with it. RBC will not regard any other person as a client and\nwill not be responsible to anyone other than the Company for providing the\nprotections offered to their clients nor for the giving of advice in relation\nto any transaction, matter or arrangement of securities of the Company\nreferred to in this Announcement. Neither RBC nor any of its affiliates,\ndirectors or employees owes or accepts any duty, liability or responsibility\nwhatsoever (whether direct or indirect, consequential, whether in contract,\ntort, in delict, under statute or otherwise) to any person who is not a client\nof RBC in connection with the Placing or any matter referred to in this\nAnnouncement.\n\nCautionary statements\n\nThis Announcement may contain, and the Company may make, \"forward-looking\nstatements\" with respect to certain of the Company's plans and its current\ngoals and expectations relating to its future financial condition,\nperformance, strategic initiatives, objectives and results. Forward-looking\nstatements sometimes use words such as \"aim\", \"anticipate\", \"target\",\n\"expect\", \"estimate\", \"intend\", \"plan\", \"goal\", \"believe\", \"seek\", \"may\",\n\"could\", \"outlook\" or other words of similar meaning. By their nature, all\nforward-looking statements involve risk and uncertainty because they relate to\nfuture events and circumstances which are beyond the control of the Company.\nAny forward-looking statements made in this Announcement by or on behalf of\nthe Company speak only as of the date they are made. Statements contained in\nthis Announcement regarding past trends or activities should not be taken as\nrepresentation that such trends or activities will continue in the future. You\nshould not place undue reliance on forward-looking statements, which speak\nonly as of the date of this Announcement.\n\nNo statement in this Announcement is intended to be a profit forecast. This\nAnnouncement does not identify or suggest, or purport to identify or suggest,\nthe risks (direct or indirect) that may be associated with an investment in\nthe Placing Shares. Any investment decisions to buy Placing Shares in the\nPlacing must be made solely on the basis of publicly available information,\nwhich has not been independently verified by the Banks. The Placing Shares\nwill not be admitted to trading on any stock exchange other than AIM.\n\nInvesting in the Placing Shares involves a substantial degree of risk. In\nmaking an investment decision, investors must perform their own investigation\nand analysis of the Company and the terms of the Placing, including the merits\nand risks involved. Prospective purchasers should not construe anything in\nthis Announcement as legal, business or tax advice. Each prospective purchaser\nshould consult its own advisors as needed to make its investment decision and\nto determine whether it is legally permitted to purchase the Placing Shares\nunder applicable legal investment or similar laws or regulations.\n\nAny indication in this Announcement of the price at which Ordinary Shares have\nbeen bought or sold in the past cannot be relied upon as a guide to future\nperformance. No statement in this Announcement is intended as a profit\nforecast or estimate for any period and no statement in this Announcement\nshould be interpreted to mean that earnings, earnings per share or income,\ncash flow from operations or free cash flow for the Company, as appropriate,\nfor the current or future years would necessarily match or exceed the\nhistorical published earnings, earnings per share or income, cash flow from\noperations or free cash flow for the Company.\n\nINFORMATION TO DISTRIBUTORS\n\nSolely for the purposes of the product governance requirements of Chapter 3 of\nthe FCA Handbook Product Intervention and Product Governance Sourcebook (the\n\"UK Product Governance Requirements\"), and disclaiming all and any liability,\nwhether arising in tort, contract or otherwise, which any “manufacturer”\n(for the purposes of the UK Product Governance Requirements) may otherwise\nhave with respect thereto, the Placing Shares have been subject to a product\napproval process, which has determined that the Placing Shares are: (i)\ncompatible with an end target market of retail investors and investors who\nmeet the criteria of professional clients and eligible counterparties, each\ndefined in paragraph 3 of the FCA Handbook Conduct of Business Sourcebook; and\n(ii) eligible for distribution through all permitted distribution channels to\nprofessional clients and eligible counterparties (the \"Target Market\nAssessment\").\n\nNotwithstanding the Target Market Assessment for the Placing Shares,\ndistributors should note that: the price of the Placing Shares may decline and\ninvestors could lose all or part of their investment; the Placing Shares offer\nno guaranteed income and no capital protection; and an investment in the\nPlacing Shares is compatible only with investors who do not need a guaranteed\nincome or capital protection, who (either alone or in conjunction with an\nappropriate financial or other adviser) are capable of evaluating the merits\nand risks of such an investment and who have sufficient resources to be able\nto bear any losses that may result therefrom.\n\nThe Target Market Assessment is without prejudice to the requirements of any\ncontractual, legal or regulatory selling restrictions in relation to the\noffering of the Placing Shares. Furthermore, it is noted that, notwithstanding\nthe Target Market Assessment, the Banks will only procure investors who meet\nthe criteria of professional clients and eligible counterparties.\n\nFor the avoidance of doubt, the Target Market Assessment does not constitute:\n(a) an assessment of suitability or appropriateness for the purposes of the UK\nProduct Governance Requirements; or (b) a recommendation to any investor or\ngroup of investors to invest in, or purchase, or take any other action\nwhatsoever with respect to the Placing Shares.\n\nEach distributor is responsible for undertaking its own target market\nassessment in respect of the Placing Shares and determining appropriate\ndistribution channels.\n\n\n[1] (#_ftnref1) Assuming that the Retail Offer is subscribed for in full and\nthe maximum number of Retail Shares is issued upon Second Admission.\n\n[2] (#_ftnref2) Assuming Admission occurs on 10 November 2026 and based on the\nEUR:GBP exchange rate of  1: 0.84514  as derived by Bloomberg on one day\nprior to the date of this Announcement.\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPRrF4130a-20261015","title":"REG-4basebio Plc: Results of Capital Raise","author":"PR Newswire","ticker":"4BB","created":"2026-10-15T14:15:48.413Z","tickers":["4BB"],"exchange":"LSE","article_body":"THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR\nINDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,\nSOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR\nDISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES IN THIS\nANNOUNCEMENT.\n\nThe information contained within this announcement is deemed by the Group to\nconstitute inside information as stipulated under the Market Abuse Regulation\n(EU) No. 596/2014 (as it forms part of domestic law by virtue of the European\nUnion (Withdrawal) Act 2018). Upon the publication of this announcement via\nthe Regulatory Information Service, this inside information is now considered\nto be in the public domain.\n\n15 October 2026\n\n4basebio PLC\n\n(“4basebio” or the “Company”)\n\nResults of Capital Raise\n\nCAMBRIDGE, UK – 15 October 2026 - 4basebio PLC (AIM: 4BB), a specialist in\nsynthetic DNA manufacturing for next-generation genomic medicines and advanced\ntherapies, is pleased to announce that it has conditionally raised gross\nproceeds of approximately £15.0 million through (i) the placing of 2,664,080\nnew Ordinary Shares  (the “Placing Shares”, comprising 485,436 VCT\nplacing shares and 2,178,644 ordinary placing shares) to institutional\ninvestors including certain existing shareholders (the “Placing”), and\n(ii) subscriptions for 1,025,239 new Ordinary Shares (the “Subscription\nShares”) by certain directors and existing shareholders including those\npertaining to the Subscription & Set-Off Agreement as defined below (the\n“Subscription”, and, together with the Retail Offer (as defined below) the\n“Capital Raise”). The Capital Raise is subject to shareholder approval.\n\nM&G Investment Management Limited (“M&G”), which currently holds 12.62 per\ncent. of the existing ordinary share capital of the Company, has subscribed\nfor 465,830 Placing Shares. Elevage Medical Technologies LLC, which currently\nholds 17.16 per cent. of the existing ordinary share capital of the Company,\nhas subscribed for 256,504 Placing Shares. The Participation of the Deutsche\nBalaton group, which currently holds 32.95 per cent. of the existing ordinary\nshare capital of the Company, in the Capital Raise is described in further\ndetail below under “2Invest Subscription and Set Off”.\n\nDirectors and Officers’ Subscriptions\n\nCertain directors and officers of the Company – namely Amy Walker, Richard\nBungay, Heikki Lanckriet and Hansjörg Plaggemars – have subscribed for\n54,366 Subscription Shares, representing aggregate gross proceeds of £0.3\nmillion pursuant to the Subscription.\n\n Name                  Position                 Number of Subscription Shares  Aggregate Subscription Amount  Resultant Shareholding  % of Enlarged Share Capital following completion of the Capital Raise[1] (#_ftn1)  \n Amy Walker            Chief Executive Officer  9,708                          £49,996.20                     58,237                  0.30%                                                                              \n Richard Bungay        Chief Financial Officer  3,883                          £19,997.45                     3,883                   0.02%                                                                              \n Heikki Lanckriet      Non-executive Director   38,834                         £199,995.10                    1,151,522               5.96%                                                                              \n Hansjörg Plaggemars   Non-executive Director   1,941                          £9,996.15                      9,608                   0.05%                                                                              \n\n2Invest Subscription and Set-off\n\nThe Company currently has a fully drawn €25 million loan facility with\n2Invest AG, a member of the Deutsche Balaton group (the “Shareholder\nLoan”). Entities in the Deutsche Balaton group currently hold, in aggregate,\n32.95 per cent. of the existing ordinary share capital of the Company.\nConcurrently with the Placing, 2Invest AG has agreed under the terms of a\nsubscription and set-off agreement dated 15 October 2026 (the “Subscription\n& Set-Off Agreement”) (i) to subscribe for 194,174 Subscription Shares in\ncash at the Issue Price, for an aggregate amount of approximately £1 million\nand (ii) to subscribe for an additional 776,699  Subscription Shares at the\nIssue Price, for an aggregate amount of approximately £4 million, payment of\nwhich shall be satisfied through the set-off against repayment of an\nequivalent amount of principal and accrued interest outstanding under the\nShareholder Loan, reducing the outstanding balance under the Shareholder Loan\nto the principal sum of €21,083,234[2] (#_ftn2) (the “2Invest Subscription\n& Set-Off”). The maturity date of the Shareholder Loan will also be extended\nby two years to 31 October 2030.\n\nThe 2Invest Subscription & Set-Off and the amendment of the Shareholder Loan\nare conditional upon completion of the Placing and the remainder of the\nSubscriptions.\n\nRelated Party Transaction\n\nThe amendment to the Shareholder Loan, pursuant to the Subscription & Set-Off\nAgreement to allow for the Subscription, is a related party transaction\npursuant to Rule 13 of the AIM Rules for Companies (the “Related Party\nTransaction”).\n\nHansjörg Plaggemars is a director of the Company and Managing Director of\n2Invest AG. As such, the Directors, with the exception of Hansjörg\nPlaggemars, having consulted with the Company's Nominated Adviser, Cairn\nFinancial Advisers LLP, consider the terms of the Related Party Transaction to\nbe fair and reasonable insofar as the Company’s AIM shareholders are\nconcerned.\n\nRetail Offer\n\nAlongside the Placing and the Subscription, the Company is proposing to raise\nup to an additional £0.5 million (before expenses) by way of a retail offer\nvia the Bookbuild Platform (the “Retail Offer”). A separate announcement\nwill be made shortly regarding the Retail Offer and its terms and conditions.\nFor the avoidance of doubt the Retail Offer forms no part of the Placing. No\npart of the Placing is conditional on the Retail Offer proceeding or on any\nminimum take-up under the Retail Offer.\n\nGeneral Meeting\n\nThe Capital Raise is conditional on shareholder approval. Accordingly, the\nCompany will convene a general meeting (the “General Meeting”) at which\nshareholders will be asked to consider and, if thought fit, pass the required\nshareholder resolutions approving the grant of new authorities to the\nDirectors to allot the Placing Shares, Subscription Shares and Retail Shares\n(the “New Shares”) and to disapply statutory pre-emption rights in respect\nof such allotments (the “Resolutions”).\n\nIt is expected that the shareholder circular and notice of General Meeting\n(the “Shareholder Circular”) will be posted within three Business Days and\nthe General Meeting will be held on or around 6 November 2026. Further details\nwill be announced in due course.\n\nAdmission and Total Voting Rights\n\nFollowing the General Meeting, the Company will make applications for the\nadmission of 2,664,080 Placing Shares, 1,025,239 Subscription Shares and the\nRetail Shares to trading on AIM (“Admission”).\n\nIt is expected that Admission of the VCT Placing Shares will occur at 8.00\na.m. on or around 9 November 2026 (“First Admission”). Admission of the\nremainder of the New Shares is expected to occur at 8.00 a.m. on or around 10\nNovember 2026, one business day following First Admission (“Second\nAdmission”).\n\nAdmission is conditional, inter alia, upon Admission becoming effective, the\nPlacing Agreement not having been terminated and becoming unconditional, and\nupon the approval of the Resolutions by Shareholders at the General Meeting.\n\nExpected Timetable of Principal Events\n\n Announcement of the Capital Raise                                                                                                                    15 October 2026                               \n Announcement of the results of the Placing                                                                                                           15 October 2026                               \n Launch of Retail Offer                                                                                                                               15 October 2026                               \n Close of Retail Offer                                                                                                                                21 October 2026                               \n General Meeting                                                                                                                                      10.00 a.m. on 6 November 2026                 \n Admission and commencement of dealings in the VCT Placing Shares on AIM (First Admission)                                                            8:00 a.m. on 9                                \n                                                                                                                                                      \t\t\tNovember 2026                              \n Crediting of the VCT Placing Shares to stock accounts in CREST                                                                                       As soon as practicable after 8:00 a.m. on 9   \n                                                                                                                                                      \t\t\tNovember 2026                              \n Admission and commencement of dealings in the Non-VCT Placing Shares, Subscription Shares and Retail Offer Shares on AIM (Second Admission)          8:00 a.m. on                                  \n                                                                                                                                                      \t\t\t10 November 2026                           \n Crediting of the Non-VCT Placing Shares, Subscription Shares and Retail Offer Shares to stock accounts in CREST                                      As soon as practicable after 8:00 a.m. on 10  \n                                                                                                                                                      \t\t\tNovember 2026                              \n Expected date of despatch of definitive share certificates for the Placing Shares, Subscription Shares and Retail Offer Shares in certificated form  By no later than 16 November 2026             \n\nEach of the times and dates above refer to London time and are subject to\nchange. Any such change will be notified to shareholders by an announcement\nthrough a Regulatory Information Service.\n\nThe person responsible for the release of this announcement on behalf of the\nCompany is Richard Bungay.\n\nContact Details\n\n4basebio PLC\n\n+44 (0)12 2396 7943\n\nDr. Amy Walker – Chief Executive Officer\n\nRichard Bungay – Chief Financial Officer\n\nRBC Capital Markets (Global Co-ordinator, Joint Bookrunner and Joint Corporate\nBroker)\n\nT: +44 (0)20 7653 4000\n\nKathryn Deegan – ECM\n\nMax Avison – ECM Syndicate\n\nSandrine Cailleteau – Healthcare Advisory\n\nCavendish Capital Markets Limited (Joint Bookrunner and Joint Corporate\nBroker)\n\nT: +44 (0)20 7220 0500\n\nGeoff Nash, Andrea Callaghan – Corporate Finance\n\nNigel Birks – Healthcare Specialist Sales\n\nCairn Financial Advisers LLP (Nominated Adviser)\n\nT: +44 (0)20 7213 0880\n\nJo Turner, Sandy Jamieson, Ed Downes\n\nICR Healthcare (Media and Investor Relations)\n\nT: +44 (0)20 3707 5700\n\nJessica Hodgson / Ashley Tapp / Philip Marriage\n\nAbout 4basebio\n\n4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the\nuse of synthetic DNA to enable next-generation therapeutics and vaccines.\nThrough its proprietary enzymatic DNA synthesis platform, 4basebio produces\nGMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability,\novercoming the limitations of plasmid-based systems. The company offers\napplication-specific DNA constructs tailored to the diverse needs of gene\ntherapies, genome editing, mRNA production, and DNA vaccines, helping partners\naccelerate proof-of-concept studies and reach clinical milestones more\nefficiently while maintaining the highest standards of safety and quality.\n\nFor more information, visit 4basebio.com  (https://www.4basebio.com/).\n\nForward-looking statements\n\nThis announcement may contain certain statements about the future outlook for\n4basebio. Although the directors believe their expectations are based on\nreasonable assumptions, any statements about future outlook may be influenced\nby factors that could cause actual outcomes and results to be materially\ndifferent.\n\n 1     Details of the person discharging managerial responsibilities / person closely associated                                                                                                             \n a)    Name                                                                                               1. Amy Walker                                                                                      \n                                                                                                          2. Richard Bungay                                                                                  \n                                                                                                          3. Heikki Lanckriet                                                                                \n                                                                                                          4. Hansjörg Plaggemars                                                                             \n 2     Reason for the notification                                                                                                                                                                           \n a)    Position/status                                                                                    1. Chief Executive Officer                                                                         \n                                                                                                          2. Chief Financial Officer                                                                         \n                                                                                                          3. Non-Executive Director                                                                          \n                                                                                                          4. Non-Executive Director                                                                          \n b)    Initial notification /Amendment                                                                    Initial notification                                                                               \n 3     Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor                                                                                         \n a)    Name                                                                                               4basebio plc                                                                                       \n b)    LEI                                                                                                213800E2DX9EAIUNCB30                                                                               \n 4     Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted     \n a)    Description of the financial instrument, type of instrument Identification code                    Ordinary Shares of 1 euro each in the Company  GB00BMCLYF79                                        \n b)    Nature of the transaction                                                                          Subscription for Ordinary Shares                                                                   \n c)    Price(s) and volume(s)                                                                             Purchase of shares:                                                                                \n       Price                                                                                              Volume(s)                                                                                          \n i     £50,000                                                                                            9,708                                                                                              \n ii.   £20,000                                                                                            3,883                                                                                              \n iii.  £200,000                                                                                           38,834                                                                                             \n iv.   £10,000                                                                                            1,941                                                                                              \n d)    Aggregated information - Aggregated volume - Price - Total Value                                   54,366515 GBp £280,000                                                                             \n e)    Date of the transaction                                                                            Subscription 15 October 2026, to settle 10 November 2026 subject to shareholder approval           \n f)    Place of the transaction                                                                           LSE, AIM Market                                                                                    \n\nIMPORTANT NOTICES\n\nNeither this Announcement, nor any copy of it, may be taken or transmitted,\npublished or distributed, directly or indirectly, in or into the United\nStates, Canada, Australia, South Africa or Japan or to any persons in any of\nthose jurisdictions or any other jurisdiction where to do so would constitute\na violation of the relevant securities laws of such jurisdiction or to any\npersons in any of those jurisdictions. This Announcement is for information\npurposes only and does not constitute an offer to sell or issue, or the\nsolicitation of an offer to buy, acquire or subscribe for any shares in the\ncapital of the Company in the United States, Canada, Australia, South Africa\nor Japan or any other state or jurisdiction in which such offer or\nsolicitation is not authorised or to any person to whom it is unlawful to make\nsuch offer or solicitation. Any failure to comply with these restrictions may\nconstitute a violation of securities laws of such jurisdictions.\n\nThe Placing Shares referred to herein have not been, and will not be,\nregistered under the United States Securities Act of 1933, (the “U.S.\nSecurities Act”), or with any securities regulatory authority of any state\nor other jurisdiction of the United States and may not be offered or sold,\npledged, taken up, exercised, resold, renounced, transferred or delivered,\ndirectly or indirectly in, into or within the United States absent\nregistration under the U.S. Securities Act, except pursuant to an exemption\nfrom, or in a transaction not subject to, the registration requirements of the\nU.S. Securities Act and in compliance with any applicable securities laws of\nany state or other jurisdiction of the United States. No public offering of\nthe shares referred to in this Announcement is being made in the United\nStates.\n\nThe Placing Shares are being offered and sold by the Company (i) to persons\noutside the United States in offshore transactions as defined in, and pursuant\nto, Regulation S under the Securities Act and (ii) to a limited number of\n“qualified institutional buyers” (as such term is used in Rule 144A under\nthe Securities Act) in the United States in non-public transactions in\nreliance on Section 4(a)(2) of the Securities Act.\n\nAll offers of Placing Shares will be made pursuant to an exemption from the\nrequirement to produce a prospectus under the Prospectus Regulation\n(Regulation (EU) 2017/1129) (the “Prospectus Regulation”) in relevant\nmember states of the European Economic Area (“EEA”) and under the UK\nPublic Offers and Admissions to Trading Regulations 2024 (“POATRs”). This\nAnnouncement is not being distributed by, nor has it been approved for the\npurposes of section 21 of the Financial Services and Markets Act 2000 (\"FSMA\")\nby, a person authorised under FSMA. This Announcement is being distributed to\npersons in the United Kingdom only in circumstances in which section 21(1) of\nFSMA does not apply. Members of the public are not eligible to take part in\nthe Placing.\n\nThis announcement is being distributed only to, and is directed only at: (a)\nif in the United Kingdom, persons who are “qualified investors” within the\nmeaning of Paragraph 15 of Schedule 1 of the POATRs who (i) are persons who\nhave professional experience in matters relating to investments falling within\nArticle 19(5) of the Financial Services and Markets Act (Financial Promotion)\nOrder 2005, as amended (the \"Order\"); or (ii) are persons who are high net\nworth entities falling within Article 49(2)(a) to (d) of the Order (and only\nwhere the conditions contained in those Articles have been, or will at the\nrelevant time be, satisfied); (b) if in the EEA, persons in member states who\nare \"qualified investors\" within the meaning of Article 2(e) of the Prospectus\nRegulation (\"Qualified Investors\"); and (c) persons to whom it may otherwise\nbe lawfully communicated, (all such persons together being referred to as\n\"Relevant Persons\"). This announcement must not be acted on or relied on by\npersons who are not Relevant Persons in the United Kingdom and in any member\nstate of the EEA. Any investment or investment activity to which this\nannouncement relates is available only to Relevant Persons in the United\nKingdom and in any member state of the EEA, and will be engaged in only with\nsuch persons.\n\nCavendish is authorised and regulated by the FCA in the United Kingdom and is\nacting as joint bookrunner, joint broker and retail offer coordinator\nexclusively for the Company and no one else in connection with this\nAnnouncement or any future transaction in connection with it. Cavendish will\nnot regard any other person as a client and will not be responsible to anyone\nother than the Company for providing the protections afforded to their clients\nnor for the giving of advice in relation to any transaction, matter or\narrangement of securities of the Company referred to in this Announcement.\nNeither Cavendish nor any of its affiliates, directors or employees owes or\naccepts any duty, liability or responsibility whatsoever (whether direct or\nindirect, consequential, whether in contract, tort, in delict, under statute\nor otherwise) to any person who is not a client of Cavendish in connection\nwith the Placing or any matter referred to in this Announcement.\n\nRBC is authorised by the Prudential Regulation Authority (“PRA”) and\nregulated by the FCA and the PRA in the United Kingdom, and is acting as joint\nbroker, global co-ordinator and joint bookrunner exclusively for the Company\nand no one else in connection with this Announcement or any future transaction\nin connection with it. RBC will not regard any other person as a client and\nwill not be responsible to anyone other than the Company for providing the\nprotections offered to their clients nor for the giving of advice in relation\nto any transaction, matter or arrangement of securities of the Company\nreferred to in this Announcement. Neither RBC nor any of its affiliates,\ndirectors or employees owes or accepts any duty, liability or responsibility\nwhatsoever (whether direct or indirect, consequential, whether in contract,\ntort, in delict, under statute or otherwise) to any person who is not a client\nof RBC in connection with the Placing or any matter referred to in this\nAnnouncement.\n\nCautionary statements\n\nThis Announcement may contain, and the Company may make, \"forward-looking\nstatements\" with respect to certain of the Company's plans and its current\ngoals and expectations relating to its future financial condition,\nperformance, strategic initiatives, objectives and results. Forward-looking\nstatements sometimes use words such as \"aim\", \"anticipate\", \"target\",\n\"expect\", \"estimate\", \"intend\", \"plan\", \"goal\", \"believe\", \"seek\", \"may\",\n\"could\", \"outlook\" or other words of similar meaning. By their nature, all\nforward-looking statements involve risk and uncertainty because they relate to\nfuture events and circumstances which are beyond the control of the Company.\nAny forward-looking statements made in this Announcement by or on behalf of\nthe Company speak only as of the date they are made. Statements contained in\nthis Announcement regarding past trends or activities should not be taken as\nrepresentation that such trends or activities will continue in the future. You\nshould not place undue reliance on forward-looking statements, which speak\nonly as of the date of this Announcement.\n\nNo statement in this Announcement is intended to be a profit forecast. This\nAnnouncement does not identify or suggest, or purport to identify or suggest,\nthe risks (direct or indirect) that may be associated with an investment in\nthe Placing Shares. Any investment decisions to buy Placing Shares in the\nPlacing must be made solely on the basis of publicly available information,\nwhich has not been independently verified by the Banks. The Placing Shares\nwill not be admitted to trading on any stock exchange other than AIM.\n\nInvesting in the Placing Shares involves a substantial degree of risk. In\nmaking an investment decision, investors must perform their own investigation\nand analysis of the Company and the terms of the Placing, including the merits\nand risks involved. Prospective purchasers should not construe anything in\nthis Announcement as legal, business or tax advice. Each prospective purchaser\nshould consult its own advisors as needed to make its investment decision and\nto determine whether it is legally permitted to purchase the Placing Shares\nunder applicable legal investment or similar laws or regulations.\n\nAny indication in this Announcement of the price at which Ordinary Shares have\nbeen bought or sold in the past cannot be relied upon as a guide to future\nperformance. No statement in this Announcement is intended as a profit\nforecast or estimate for any period and no statement in this Announcement\nshould be interpreted to mean that earnings, earnings per share or income,\ncash flow from operations or free cash flow for the Company, as appropriate,\nfor the current or future years would necessarily match or exceed the\nhistorical published earnings, earnings per share or income, cash flow from\noperations or free cash flow for the Company.\n\nINFORMATION TO DISTRIBUTORS\n\nSolely for the purposes of the product governance requirements of Chapter 3 of\nthe FCA Handbook Product Intervention and Product Governance Sourcebook (the\n\"UK Product Governance Requirements\"), and disclaiming all and any liability,\nwhether arising in tort, contract or otherwise, which any “manufacturer”\n(for the purposes of the UK Product Governance Requirements) may otherwise\nhave with respect thereto, the Placing Shares have been subject to a product\napproval process, which has determined that the Placing Shares are: (i)\ncompatible with an end target market of retail investors and investors who\nmeet the criteria of professional clients and eligible counterparties, each\ndefined in paragraph 3 of the FCA Handbook Conduct of Business Sourcebook; and\n(ii) eligible for distribution through all permitted distribution channels to\nprofessional clients and eligible counterparties (the \"Target Market\nAssessment\").\n\nNotwithstanding the Target Market Assessment for the Placing Shares,\ndistributors should note that: the price of the Placing Shares may decline and\ninvestors could lose all or part of their investment; the Placing Shares offer\nno guaranteed income and no capital protection; and an investment in the\nPlacing Shares is compatible only with investors who do not need a guaranteed\nincome or capital protection, who (either alone or in conjunction with an\nappropriate financial or other adviser) are capable of evaluating the merits\nand risks of such an investment and who have sufficient resources to be able\nto bear any losses that may result therefrom.\n\nThe Target Market Assessment is without prejudice to the requirements of any\ncontractual, legal or regulatory selling restrictions in relation to the\noffering of the Placing Shares. Furthermore, it is noted that, notwithstanding\nthe Target Market Assessment, the Banks will only procure investors who meet\nthe criteria of professional clients and eligible counterparties.\n\nFor the avoidance of doubt, the Target Market Assessment does not constitute:\n(a) an assessment of suitability or appropriateness for the purposes of the UK\nProduct Governance Requirements; or (b) a recommendation to any investor or\ngroup of investors to invest in, or purchase, or take any other action\nwhatsoever with respect to the Placing Shares.\n\nEach distributor is responsible for undertaking its own target market\nassessment in respect of the Placing Shares and determining appropriate\ndistribution channels.\n\n\n[1] (#_ftnref1) Assuming that the Retail Offer is subscribed for in full and\nthe maximum number of Retail Shares is issued upon Second Admission.\n\n[2] (#_ftnref2) Assuming Admission occurs on 10 November 2026 and based on the\nEUR:GBP exchange rate of  1: 0.84514  as derived by Bloomberg on one day\nprior to the date of this Announcement.\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-15T14:15:48.461804815Z","server_sent_at_ms":1792073748461},"received_at":"2026-10-15T14:15:48.630Z","source_url":null},"analysis":{"id":"158821","press_release_id":"170639","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["dilution: approximately 3.7 million new shares via placing and subscription, plus retail offer shares, subject to shareholder approval","related party transaction: £4 million of the raise settled via set-off against the 2Invest Shareholder Loan; Hansjörg Plaggemars sits on both sides as 4basebio NED and Managing Director of 2Invest AG","equity raise still required for a pre-revenue biotech, suggesting ongoing cash burn","Capital Raise is conditional on a general meeting and could still fail to complete"],"eventType":"offering","narrative":"4basebio has conditionally raised approximately £15.0 million gross through a placing of 2,664,080 new shares to institutional investors and subscriptions for 1,025,239 new shares, alongside a proposed retail offer of up to £0.5 million.\n\nMajor holders participated meaningfully: M&G (12.62% holder) subscribed for 465,830 placing shares, Elevage Medical Technologies (17.16%) for 256,504, and directors including CEO Amy Walker and CFO Richard Bungay subscribed £0.3 million in aggregate.\n\nUnder a related-party subscription and set-off agreement, 2Invest AG (Deutsche Balaton group, 32.95% holder) will subscribe £5 million of shares, with £4 million satisfied by offsetting the €25 million Shareholder Loan, cutting its balance to €21,083,234 and extending maturity two years to 31 October 2030.\n\nThe raise is conditional on shareholder approval at a general meeting expected around 6 November 2026, with first admission of the new shares to AIM anticipated on or around 9 November 2026.","sentiment":"mixed","agentHooks":{"shouldPost":true,"suggestedAngle":"£15m raise with heavy insider and major-holder participation plus a shareholder-loan set-off that extends the debt runway to 2030 -- dilution offset by balance-sheet extension."},"keyFigures":{"dealValueUsd":"£15.0 million gross (Capital Raise, before Retail Offer)","offeringPrice":"implied ~£5.15 per share (issue price; per PDMR table, 9,708 shares for £49,996.20)","sharesOffered":"2,664,080 Placing Shares + 1,025,239 Subscription Shares, plus up to £0.5m of Retail Offer Shares","customDimensions":{"mg_stake":"12.62%","elevage_stake":"17.16%","retail_offer_target":"£0.5 million","general_meeting_date":"on or around 6 November 2026","deutsche_balaton_stake":"32.95%","pdmr_subscription_gross":"£0.3 million (54,366 shares by four directors/officers)","2invest_cash_subscription":"£1 million (194,174 shares)","2invest_setoff_subscription":"£4 million (776,699 shares, offset against Shareholder Loan)","shareholder_loan_maturity_extended_to":"31 October 2030","shareholder_loan_outstanding_after_setoff":"€21,083,234"}},"quotedText":"conditioned raised gross proceeds of approximately £15.0 million","namedEntities":{"people":[{"name":"Amy Walker","role":"Chief Executive Officer"},{"name":"Richard Bungay","role":"Chief Financial Officer"},{"name":"Heikki Lanckriet","role":"Non-executive Director"},{"name":"Hansjörg Plaggemars","role":"Non-executive Director and Managing Director of 2Invest AG"}],"products":["synthetic DNA (GMP-grade)","mRNA","enzymatic DNA synthesis platform"],"companies":[{"name":"4basebio PLC","ticker":"4BB","relationship":"issuer/filer"},{"name":"M&G Investment Management Limited","relationship":"existing shareholder (12.62%) and placing subscriber"},{"name":"Elevage Medical Technologies LLC","relationship":"existing shareholder (17.16%) and placing subscriber"},{"name":"2Invest AG","relationship":"lender under €25m Shareholder Loan; Deutsche Balaton group member (32.95% holder) and subscriber"},{"name":"Deutsche Balaton group","relationship":"major shareholder (32.95%)"},{"name":"RBC Capital Markets","relationship":"global co-ordinator, joint bookrunner and joint corporate broker"},{"name":"Cavendish Capital Markets Limited","relationship":"joint bookrunner, joint corporate broker and retail offer coordinator"},{"name":"Cairn Financial Advisers LLP","relationship":"nominated adviser"}],"dollarAmounts":[{"amount":"£15.0 million","context":"gross proceeds of the Capital Raise (placing plus subscriptions)"},{"amount":"£0.5 million","context":"maximum Retail Offer proceeds (before expenses)"},{"amount":"£0.3 million","context":"aggregate gross proceeds of directors' and officers' subscriptions"},{"amount":"€25 million","context":"fully drawn Shareholder Loan facility with 2Invest AG"},{"amount":"£1 million","context":"2Invest cash subscription for 194,174 shares"},{"amount":"£4 million","context":"2Invest subscription for 776,699 shares satisfied via set-off against the Shareholder Loan"},{"amount":"€21,083,234","context":"outstanding Shareholder Loan principal after set-off"},{"amount":"£280,000","context":"total value of PDMR share subscriptions"}]},"materialImpact":{"score":3,"reasoning":"Conditionally raised ~£15.0 million gross via placing and subscriptions (~3.7 million new shares) plus a proposed £0.5 million retail offer, diluting existing holders. Offsetting the dilution, insider participation from directors and major shareholders and a two-year extension of the €25 million 2Invest shareholder loan to 31 October 2030 materially improve the balance-sheet runway."},"tickerRelevance":{"others":[],"primary":"4BB"},"globalImportance":28,"audienceRelevance":22,"eventTypeSecondary":["debt_offering","dilution"],"importanceComponents":{"tickerTier":"small-cap AIM-listed","eventGravity":"equity capital raise with related-party debt set-off","householdBrandBoost":0,"marketCapAdjustment":"material raise relative to likely market cap","retailFavoriteBoost":"minor retail offer component"}},"event_type":"offering","event_type_secondary":["debt_offering","dilution"],"sentiment":"mixed","material_impact_score":3,"narrative":"4basebio has conditionally raised approximately £15.0 million gross through a placing of 2,664,080 new shares to institutional investors and subscriptions for 1,025,239 new shares, alongside a proposed retail offer of up to £0.5 million.\n\nMajor holders participated meaningfully: M&G (12.62% holder) subscribed for 465,830 placing shares, Elevage Medical Technologies (17.16%) for 256,504, and directors including CEO Amy Walker and CFO Richard Bungay subscribed £0.3 million in aggregate.\n\nUnder a related-party subscription and set-off agreement, 2Invest AG (Deutsche Balaton group, 32.95% holder) will subscribe £5 million of shares, with £4 million satisfied by offsetting the €25 million Shareholder Loan, cutting its balance to €21,083,234 and extending maturity two years to 31 October 2030.\n\nThe raise is conditional on shareholder approval at a general meeting expected around 6 November 2026, with first admission of the new shares to AIM anticipated on or around 9 November 2026.","key_figures":{"dealValueUsd":"£15.0 million gross (Capital Raise, before Retail Offer)","offeringPrice":"implied ~£5.15 per share (issue price; per PDMR table, 9,708 shares for £49,996.20)","sharesOffered":"2,664,080 Placing Shares + 1,025,239 Subscription Shares, plus up to £0.5m of Retail Offer Shares","customDimensions":{"mg_stake":"12.62%","elevage_stake":"17.16%","retail_offer_target":"£0.5 million","general_meeting_date":"on or around 6 November 2026","deutsche_balaton_stake":"32.95%","pdmr_subscription_gross":"£0.3 million (54,366 shares by four directors/officers)","2invest_cash_subscription":"£1 million (194,174 shares)","2invest_setoff_subscription":"£4 million (776,699 shares, offset against Shareholder Loan)","shareholder_loan_maturity_extended_to":"31 October 2030","shareholder_loan_outstanding_after_setoff":"€21,083,234"}},"named_entities":{"people":[{"name":"Amy Walker","role":"Chief Executive Officer"},{"name":"Richard Bungay","role":"Chief Financial Officer"},{"name":"Heikki Lanckriet","role":"Non-executive Director"},{"name":"Hansjörg Plaggemars","role":"Non-executive Director and Managing Director of 2Invest AG"}],"products":["synthetic DNA (GMP-grade)","mRNA","enzymatic DNA synthesis platform"],"companies":[{"name":"4basebio PLC","ticker":"4BB","relationship":"issuer/filer"},{"name":"M&G Investment Management Limited","relationship":"existing shareholder (12.62%) and placing subscriber"},{"name":"Elevage Medical Technologies LLC","relationship":"existing shareholder (17.16%) and placing subscriber"},{"name":"2Invest AG","relationship":"lender under €25m Shareholder Loan; Deutsche Balaton group member (32.95% holder) and subscriber"},{"name":"Deutsche Balaton group","relationship":"major shareholder (32.95%)"},{"name":"RBC Capital Markets","relationship":"global co-ordinator, joint bookrunner and joint corporate broker"},{"name":"Cavendish Capital Markets Limited","relationship":"joint bookrunner, joint corporate broker and retail offer coordinator"},{"name":"Cairn Financial Advisers LLP","relationship":"nominated adviser"}],"dollarAmounts":[{"amount":"£15.0 million","context":"gross proceeds of the Capital Raise (placing plus subscriptions)"},{"amount":"£0.5 million","context":"maximum Retail Offer proceeds (before expenses)"},{"amount":"£0.3 million","context":"aggregate gross proceeds of directors' and officers' subscriptions"},{"amount":"€25 million","context":"fully drawn Shareholder Loan facility with 2Invest AG"},{"amount":"£1 million","context":"2Invest cash subscription for 194,174 shares"},{"amount":"£4 million","context":"2Invest subscription for 776,699 shares satisfied via set-off against the Shareholder Loan"},{"amount":"€21,083,234","context":"outstanding Shareholder Loan principal after set-off"},{"amount":"£280,000","context":"total value of PDMR share subscriptions"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-15T14:15:59.019Z","global_importance":28,"audience_relevance":22,"importance_components":{"tickerTier":"small-cap AIM-listed","eventGravity":"equity capital raise with related-party debt set-off","householdBrandBoost":0,"marketCapAdjustment":"material raise relative to likely market cap","retailFavoriteBoost":"minor retail offer component"}},"durationMs":10368,"modelName":"glm-5.3-flashx"}}